The DOI matches its Crossref record.
Intranasal Drug Delivery for Brain Targeting
Abstract
Many drugs are not being effectively and efficiently delivered using conventional drug delivery approach to brain or central nervous system (CNS) due to its complexity. The brain and the central nervous system both have limited accessibility to blood compartment due to a number of barriers. Many advanced and effective approaches to brain delivery of drugs have emerged in recent years. Intranasal drug delivery is one of the focused delivery options for brain targeting, as the brain and nose compartments are connected to each other via the olfactory route and via peripheral circulation. Realization of nose to brain transport and the therapeutic viability of this route can be traced from the ancient times and has been investigated for rapid and effective transport in the last two decades. Various models have been designed and studied by scientists to establish the qualitative and quantitative transport through nasal mucosa to brain. The development of nasal drug products for brain targeting is still faced with enormous challenges. A better understanding in terms of properties of the drug candidate, nose to brain transport mechanism, and transport to and within the brain is of utmost importance. This review will discuss some pertinent issues to be considered and challenges to brain targeted intranasal drug delivery. A few marketed and investigational drug formulations will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Intranasal delivery: Physicochemical and therapeutic aspects
Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., & Quay, S. C. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.025 · Cited by 598
Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier
Upadhyay, R. K. (2014) · BioMed Research International · doi:10.1155/2014/869269 · Cited by 528
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435
Self-citationMd, S., Khan, R. A., Mustafa, G., Chuttani, K., Baboota, S., Sahni, J. K., & Ali, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.007 · Cited by 306
Lee, M. R., Scheidweiler, K. B., Diao, X. X., Akhlaghi, F., Cummins, A., Huestis, M. A., Leggio, L., & Averbeck, B. B. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.27 · Cited by 235
Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting
Kumar, M., Misra, A., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802476504 · Cited by 179
Self-citationLong, Y., Yang, Q., Xiang, Y., Zhang, Y., Wan, J., Liu, S., Li, N., & Peng, W. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104795 · Cited by 151
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145
The blood-brain barrier and nasal drug delivery to the central nervous system
Miyake, M. M., & Bleier, B. S. (2015) · American Journal of Rhinology & Allergy · doi:10.2500/ajra.2015.29.4149 · Cited by 106
Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review
Rassu, G., Soddu, E., Cossu, M., Gavini, E., Giunchedi, P., & Dalpiaz, A. (2016) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.05.002 · Cited by 87
Nageeb El-Helaly, S., Abd Elbary, A., Kassem, M. A., & El-Nabarawi, M. A. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1309476 · Cited by 69
“When the drug is administered via IN route, it can enter into the brain via three different paths (Vyas et al., 2005).”
BackgroundNasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries
Dalpiaz, A., Fogagnolo, M., Ferraro, L., Capuzzo, A., Pavan, B., Rassu, G., Salis, A., Giunchedi, P., & Gavini, E. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.09.013 · Cited by 63
Metadata
- Authors
- Vyas, T., Shahiwala, A., Marathe, S., & Misra, A.
- Venue
- Current Drug Delivery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-04-01
- Volume
- 2
- Issue
- 2
- Pages
- 165-175
- ISSN
- 1567-2018 (ISSN-L)
- OpenAlex
- W2000772129
- Cited by
- 257
- References
- 0
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.